Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153758 | 0.95 | GRIN2B (0.33) | CYP17A1GRIN2BKCNH2ESR1ESR2 | |
| SCHEMBL3165290 | 0.93 | CYP17A1 (0.35) | CYP17A1GRIN2BKCNH2ESR1ESR2 | |
| SCHEMBL3159192 | 0.93 | GRIN2B (0.32) | CYP17A1GRIN2BKCNH2ESR1ESR2 | |
| SCHEMBL3168016 | 0.91 | NCEH1 (0.36) | CYP17A1GRIN2BESR1ESR2S1PR1 | |
| SCHEMBL3159176 | 0.91 | CACNA1H (0.33) | GRIN2BKCNH2ESR1ESR2S1PR1 | |
| SCHEMBL3161794 | 0.89 | MPL (0.38) | CYP17A1S1PR1S1PR3S1PR5 | |
| SCHEMBL3172728 | 0.89 | GRM2 (0.35) | GRIN2BS1PR1S1PR3S1PR5GRM2 | |
| SCHEMBL3161333 | 0.88 | RARB (0.40) | CYP17A1S1PR1S1PR3S1PR5 | |
| SCHEMBL3166589 | 0.87 | RARB (0.42) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3158315 | 0.87 | RARB (0.42) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1452514-B1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK & CHEMICALS (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-1273562-B1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK & CHEMICALS (JP) | 2009-07-22 | — | — | EP | disclosed |
| CN-1291958-C | Naphthacridine derivative and liquid crystal composite containing it | DAINIPPON INK CHEMICAL IND CO (JP) | 2006-12-27 | — | — | CN | disclosed |
| US-7145047-B2 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-12-05 | — | — | US | disclosed |
| EP-0952135-B1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK & CHEMICALS (JP) | 2005-01-05 | — | — | EP | disclosed |
| EP-1452514-A1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20030136944-A1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1273562-A1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-01-08 | — | — | EP | disclosed |
| US-6468607-B1 | MISCIBILITY, LARGE BIREFRINGENCE INDEX, NO STRONGLY POLAR GROUP IN ITS MOLECULE AND THUS CAN ALSO BE USED FOR ACTIVE MATRIX DRIVING, WIDE TEMPERATURE RANGE AND REQUIRES A HIGH SPEED RESPONSE AND A LOW VOLTAGE DRIVING | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-0952135-A1 | Naphthalene derivative and liquid crystal composition comprising the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030136944-A1 | Naphthalene derivative and liquid crystal composition comprising the same | NLK, NOTCH1, NOTCH4 | CYP17A1 425/4885GRIN2B 4324/4885KCNH2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.